Cerus Corporation (NDAQ:CERS) shares moved up $0.27, or 3.52%, to $7.94 after the company announced that it was evaluating strategic alternatives for its immunotherapy vaccine businesses. Cerus has three immunotheraputic product candidates with one in early
stage human clinical trials and another for which an investigational
new drug application is slated to be filed in mid-2007. The products
are designed to stimulate immune pathways to target and attack cancer
cells and infectious diseases. These strategic options could include a sale, merger, spinoff, or partnership with another company. Some investors had voiced concerns over the units valuation in the past and this move will enable the company to unlock the value for shareholders. This makes CERS a stock
worth watching!
Related CompaniesAntigenics, Inc. (AGEN)Cell Genesys, Inc. (CEGE)Dendreon Corporation (DNDN)